$AMRX Income Statement | Understand Stock

$AMRX

$21.44 +$0.42 (2.0%) Close

$AMRX Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Operations

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Net revenue
Cost of goods sold
Cost of goods sold impairment charges
Gross profit
Selling, general and administrative
Research and development
In-process research and development impairment charges
Intellectual property legal development expenses
Acquisition, transaction-related and integration expenses
Restructuring and other charges
Property losses and associated expenses, net
Change in fair value of contingent consideration
Insurance recoveries for property losses and associated expenses, net
(Credit) charges related to legal matters, net
Other operating income
Operating income
Other (expense) income:
Interest expense, net
Foreign exchange gain (loss), net
Loss on refinancing
Gain on sale of international businesses
Gain from reduction of tax receivable agreement liability
Increase in tax receivable agreement liability
Other income, net
Total other expense, net

Income (loss) before income taxes
Provision for income taxes
Net income (loss)
Less: Net income attributable to non-controlling interests
Net loss attributable to Amneal Pharmaceuticals, Inc. before accretion of redeemable non-controlling interest
Accretion of redeemable non-controlling interest
Net loss attributable to Amneal Pharmaceuticals, Inc.
Net income (loss) attributable to Amneal Pharmaceuticals, Inc.
Net income (loss) per share attributable to Amneal Pharmaceuticals, Inc.’s Class A common stockholders:
Basic (in dollars per share)
Diluted (in dollars per share)
Weighted-average common shares outstanding:
Basic (in shares)
Diluted (in shares)

Comments